Elucid

Elucid is an innovative AI medical technology company dedicated to enhancing the understanding and management of atherosclerosis. At the forefront of their offerings is PlaqueIQ™, the first FDA-cleared, non-invasive plaque analysis tool founded on objective histology rather than subjective assessments. This powerful software enables comprehensive visualization and quantification of plaque composition and vessel structure, providing critical insights that can guide patient-specific treatment pathways.

Elucid's solutions are designed to address the significant health challenge posed by cardiovascular disease, which remains a leading cause of mortality worldwide. Approximately half of Americans aged between 45 and 84 are unaware they have atherosclerosis, highlighting the need for accurate diagnostic tools. With PlaqueIQ, physicians gain access to detailed analyses including 3D representations of vessel structures and distinct classifications of plaque components, such as lipid-rich necrotic cores and calcified deposits. Through these advancements, Elucid empowers healthcare professionals to make informed decisions, ultimately improving patient outcomes and reducing the risk of heart attacks and strokes.